Evidence regarding the use of BRCA status or homologous recombination competency to guide treatment selection in BC is strongest in the setting of metastatic disease, and several recent clinical studies have evaluated platinum salts and PARPi in patients with advanced or metastatic BC and BRCA1/2m. The gene discussed is BRCA1; the disease is breast cancer.